PeptideSearch

PT-141

Approved medicine

Get notified when the evidence changes.

The FDA has approved a version of this as a medicine, so it has been through large studies in people.

Compiled and reviewed by the PeptideSearch Editorial Team · Status checked 2026-06-05

Also called Bremelanotide / Vyleesi / Melanocortin agonist

A medicine acting on brain signals linked to sexual desire, approved for low desire in premenopausal women.

The basics

What is it?
An approved medicine that acts on brain signals tied to sexual desire.
What do we know?
In studies in women with low sexual desire, some reported improvement. It is approved for that use.
What do we still not know?
How large the benefit really is day to day, and how well it works for anyone else.

Official status: Pharmacies may compound it · Checked 2026-06-05

Can a doctor prescribe this?

Small pharmacy (503A)
Never put forward to FDA
Large outsourcing facility (503B)
Never put forward to FDA

FDA approved as bremelanotide for hypoactive sexual desire disorder in premenopausal women.

Why both lines above can be true: this compound is the active ingredient of a drug the FDA has already approved, and a pharmacy may compound with a bulk substance that is “a component of a drug approved by the Secretary” — a separate route in the law from the list of substances put forward for review. So it never had to be nominated for that list. The wording is in section 503A(b)(1)(A)(i)(II) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353a). The substance must also be made by an FDA-registered establishment and come with a certificate of analysis for each lot.

503A is a pharmacy making a single prescription for one patient. 503B is a facility making batches. They are governed by separate lists. Where a category is shown, it is a position on the FDA's list of substances that have been put forward and are still being worked through — not the final list, which is set by rulemaking. Category 1 means the FDA does not plan to act against a pharmacy that makes it while the review runs.

Lab suppliers we list: 14

Doses used in research

Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.

Spot an error? corrections@peptidesearch.org

We'll email you when a new study, trial or status change lands for PT-141. Unsubscribe in one click.